# Biotin-Acridine Red Cell Exchange Kinetics

> **NCT07155031** · PHASE2 · WITHDRAWN · sponsor: **Cerus Corporation**

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DEVICE:** Pathogen reduced red blood cells

## Key facts

- **NCT ID:** NCT07155031
- **Lead sponsor:** Cerus Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-10-15
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study has been suspended due to a lack of funding. The protocol will be reconsidered within the next 6-12 months if/as funding becomes available.
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155031, "Biotin-Acridine Red Cell Exchange Kinetics". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07155031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*